Evidence map›Paper›PMID 32047770›Full record

ReviewAnnals of translational medicine2019

Concise update on colorectal cancer epidemiology.

Camilla Mattiuzzi, Fabian Sanchis-Gomar, Giuseppe Lippi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Effects of culturally targeted message framing on colorectal cancer screening among African Americans.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2021
    Trial
  8. Article
  9. [Colorectal cancer diagnosis method based on dynamic gland-aware and tissue soft-clustering].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Article
  10. Article
  11. Integrative single-cell analysis revealsFrontiers in immunology · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. RETRACTED: The Impact ofInternational journal of molecular sciences · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Camilla MattiuzziService of Clinical Governance, Provincial Agency for Social and Sanitary Services, Trento, Italy.
Fabian Sanchis-GomarDepartment of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain.
Giuseppe LippiSection of Clinical Biochemistry, University of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is a type of gastrointestinal malignancy originating from either the colon or rectum. In this short report we provide a concise update on recent colorectal cancer statistics, especially concerning frequency, mortality, life expectancy and risk factors. Overall, colorectal cancer is the third more frequent malignant disease around the world (1.85 million of new cases/years; 10.2% of total malignancies), with 2.27% cumulative risk of onset between 0-74 years. The age-standardized rate increases by over 10-fold before the age of 50 up to ≥85 years, whilst men have ~50% enhanced risk compared to women (the 0-74 years risk is 2.75% in men and 1.83% in women, respectively). Although colorectal cancer screening has contributed to slightly reduce the number of diagnoses at advanced stages, most cases are only identified after symptoms onset. The number of worldwide deaths for colorectal cancer has been estimated at 0.88 million in 2018, representing ~1.4% of all-cause and ~8.9% of cancer-related deaths, with over 30% increase occurred during the past 15 years and a further 25% growth expected by the year 2030. The cumulative risk of dying for colorectal cancer is 0.92% between 0-74 years (1.14% in men and 0.72% in women, respectively). The 5-year cumulative survival is 64-67%, being 89-90% in patients with localized cancer, 70-71% in those with regional cancer, decreasing to 14-15% in those with distant cancer. The leading risk factors include familial history, pre-cancerous conditions, tall stature, physical inactivity, overweight, large intake of alcoholic beverages, high consumption of red or processed meat, as well as modest intake of dairy products and foods containing wholegrains or dietary fibre. The association between colorectal cancer and human development index suggests that reinforcement or timely establishment of preventive measures and accurate screening programs may be advisable, especially in countries undergoing considerable societal and economic changes.

Indexed as

Colorectal cancerepidemiologyfrequencymortalitystatistics

Identifiers

PMID32047770
PMCPMC7011596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.